ArticleGynecologic oncology2025
Uterine leiomyosarcoma progression: A study of serial recurrences.
Article in Gynecologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular and Genetic Landscape of Intravenous Leiomyomatosis: A Narrative Review.Cancer innovation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundUterine leiomyosarcomas (uLMS) have high recurrence rates and are frequently characterized by genetic alterations affecting TP53 and RB1. We sought to compare the molecular profiles of primary uLMS and matched serial recurrences to assess tumor evolution.
methodsPatients diagnosed with uLMS between 1/1/2000-11/31/2020 who had primary tumor, ≥2 serial recurrences, and normal tissue available were identified. Samples were microdissected to enhance tumor purity and subjected to tumor-normal targeted DNA next-generation sequencing (NGS).
resultsNGS was performed on 42 tumor samples from 10 patients. The median age at diagnosis was 54 years (range 30-69). The median number of recurrences was 3 (range 2-7). At least one homozygous deletion affecting RB1 (50 %), PTEN (30 %), TP53 (30 %), and/or BRCA2 (20 %), as well as clonal mutations affecting TP53 (30 %) and ATRX (10 %), were early events and present across subsequent samples of a given patient. In addition, non-pathogenic missense mutations were frequently shared across samples from a given case. In general, no additional cancer gene mutations were acquired during progression, including ESR1 hotspot mutations. Chromosomal instability was found to be significantly higher, albeit marginally so, in the recurrences compared to the patient-matched primary tumors (median fraction of genome altered 31 % v 29 %, p = 0.043).
conclusionPrimary uLMS and subsequent recurrences display genomic intra-individual concordance, with sustained driver cancer gene alterations over time. Chromosomal instability was higher in recurrent tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.